Notice of Results

Hutchison China Meditech Limited
26 February 2007


                     

For Immediate Release

                                                               26 February 2007


                        Hutchison China MediTech Limited
                                    (AIM: HCM)

                          Notice of Preliminary Results

Hutchison China MediTech Limited ('Chi-Med') will announce its preliminary 
results for the year ended 31 December 2006 on Wednesday, 21 March 2007.

                                      Ends

Enquiries

Chi-Med                                          Telephone: [phone]
Christian Hogg, CEO

Citigate Dewe Rogerson                           Telephone: [phone]
Anthony Carlisle                                            [phone]
Yvonne Alexander                                            [phone]

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based 
primarily in China and was admitted to trading on the Alternative Investment 
Market of the London Stock Exchange in May 2006. Chi-Med is focused on 
researching, developing, manufacturing, and selling pharmaceuticals, health 
supplements and other consumer health and personal care products derived from 
Traditional Chinese Medicine ('TCM') and botanical ingredients. Its overall aim 
is to draw on the untapped wealth of knowledge and history of usage in the TCM 
industry to develop products for the global market. Chi-Med has three 
complementary businesses: drug R&D, China healthcare and consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international 
corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.



                      This information is provided by RNS
            The company news service from the London Stock Exchange